Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms

Who We Are

At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.

Our Approach: Optimizing Treatments for Neuronal Excitability Disorders

Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.

Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.

Our Pipeline

Our two lead drug candidates have clinically validated mechanisms of action for neurological diseases and have demonstrated encouraging clinical and preclinical results. We are developing ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders and focal onset seizures. These compounds are designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions.

Learn More

Our Experienced Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market. Eliem is also advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
Leadership Team Board of Directors
Bob Azelby
President and Chief Executive Officer
Bob Azelby
President and Chief Executive Officer
Bob most recently served as the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for $6.5 billion annual net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions, including Vice President of US Oncology Sales, Vice President of North American Commercial Operations, General Manager for Amgen Netherlands and Senior Marketing Director. He is currently a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics Board of Directors. Bob received his undergraduate degrees in economics and religious studies from the University of Virginia and his master of business administration from Harvard University.
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Valerie is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and she was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for pain and across a number of other therapeutic areas including neurology, psychiatry, gastrointestinal disorders and sensory biology. Valerie trained as an electrophysiologist and completed her doctorate at the University of Bordeaux.
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
Erin has more than 20 years of cross-functional experience leading strategic and operational initiatives in the biopharmaceutical industry. Erin was Chief Operating Officer of Alder BioPharmaceuticals, leading the company’s readiness for launch of its first therapy, including enterprise planning around supply chain, compliance and information technology. She led the company’s $2.3 billion sale to H. Lundbeck in 2019. Prior to Alder, Erin worked at Amgen for 15 years in a variety of roles in the corporate development, finance and commercial organizations. Her most recent role was General Manager of Amgen Taiwan, where she managed a portfolio of six commercialized products. Erin worked in Hong Kong as an Executive Director for the Japan Asia-Pacific region during its initial build. She began her career as an investment banker focused on biotech M&A and financing in the healthcare group at Merrill Lynch & Co. Erin is currently a member of the Neoleukin Therapeutics Board of Directors and serves as President of the Seattle chapter of the Healthcare Businesswomen’s Association (HBA). She holds a bachelor of arts in economics from Yale University.
James Bucher, J.D.
Executive Vice President & General Counsel
James Bucher, J.D.
Executive Vice President & General Counsel
Jim served as Executive Vice President and General Counsel of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Jim was a standing member of Alder’s Executive Team, participating in the management of all aspects of Alder’s strategy and operations, with direct responsibility for the company’s legal affairs, intellectual property, risk management, and compliance. Prior to joining Alder, Jim was Vice President of Corporate Legal Affairs and Secretary as well as the Corporate Compliance Officer of Exelixis, a NASDAQ-listed biopharmaceutical company. He was a partner at the international law firm Shearman & Sterling LLP, serving with the firm for 16 years. Jim has significant experience with capital raising, including execution of six equity and convertible debt financings generating over $900 million in capital for Alder and eight equity and debt financings generating over $1 billion in capital for Exelixis. Jim holds a juris doctorate with distinction from Emory University School of Law and a bachelor of arts in biology from Colgate University.
Amy Chappell, M.D.
Chief Medical Officer
Amy Chappell, M.D.
Chief Medical Officer
Amy has 32 years of CNS clinical drug development experience first at Eli Lilly and Company, followed by extensive consulting for small and large pharmaceutical companies. Her most recent position was Vice President, Neuroscience, at PPD, a contract research organization. Amy has deep expertise in translational neuroscience and in all phases of clinical drug development across a wide range of neurological indications including epilepsy, ALS, Parkinson’s, Alzheimer’s, multiple pain types, migraine and multiple sclerosis. She has interacted with multiple regulatory agencies and was the medical lead on the development and NDA submission of duloxetine for fibromyalgia that resulted in an FDA approval. She is the author of many peer-reviewed scientific publications. Amy is certified by the American Board of Neurology and Psychiatry (neurology with special competency in child), the American Academy of Pediatrics (specialty certification) and the American Board of Lifestyle Medicine. She has 40 years of clinical practice experience in child and adult neurology and holds active Florida and Indiana medical licenses. She received her bachelor of science from Antioch College and medical degree from the Indiana University School of Medicine. She completed her post-doctoral training at the Johns Hopkins Hospital (pediatric residency and epilepsy fellowship) and the Indiana University Medical Center (neurology residency).
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Jo is a neuropsychologist with over 18 years’ experience working in clinical development in the pharmaceutical industry with a focus on pain and migraine. She has held positions in both clinical operations and clinical strategy including leading multidisciplinary clinical teams at Roche, GSK, Convergence Pharmaceuticals and Biogen. Jo was a founding member of Convergence Pharmaceuticals Ltd and a member of the leadership team. As the Head of Clinical Operations at Convergence, she was responsible for designing and managing the full-service outsourcing of phase 1 and 2 clinical studies in pain. She was also responsible for establishing and maintaining the Quality System.
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew Levin, M.D., Ph.D.
(Chairman)
Andrew is a Co-Founder of Eliem Therapeutics and Chairman of the Board of Directors. In addition to co-founding Eliem, Andrew spearheads drug discovery efforts at RA Capital Management, L.P. that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that he served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. He holds a bachelor of science in mechanical engineering from Princeton University, a doctorate in biomedical engineering from the Massachusetts Institute of Technology and a medical degree from Harvard Medical School.
Bob Azelby
Bob Azelby
Bob most recently served as the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.3 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for $6.5 billion in annual net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions including Vice President of US Oncology Sales, Vice President of North American Commercial Operations, General Manager for Amgen Netherlands, Senior Marketing Director, etc. He is currently a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics’ Board of Directors. Bob received his undergraduate degrees in economics and religious studies from the University of Virginia and his master of business administration from Harvard University.
Judith Dunn, Ph.D.
Judith Dunn, Ph.D.
Judy is the President and Head of R&D at Fulcrum Therapeutics.  Prior to this role, Judy was an Entrepreneur-in-Residence at Atlas Venture, where she focused on new company creation. Previously, Judy served as Vice President and Global Head of Clinical Development at Roche in Basel, Switzerland, and Head of the Roche Innovation Center in NYC. She has held leadership positions in both the research and commercial neuroscience divisions of Pfizer and in clinical psychiatry at Sepracor. Judy is currently an independent board director at Evolution Research Group and a member of the NYC Mayor’s Advisory Council on Life Sciences. She has also served as a scientific advisor to the Tri-Institutional Therapeutics Discovery Institute and as a board member of the Partnership for NY Fund.
Leone Patterson
Leone Patterson
Leone is president and chief financial officer of Adverum Biotechnologies, Inc., a clinical-stage gene therapy company focused on ocular and rare diseases. She has over 20 years of experience in the biotechnology industry. Prior to Adverum, Leone served as Chief Financial Officer of Diadexus, Inc. Earlier, she was Chief Financial Officer of Transcept Pharmaceuticals, Inc. until it was acquired by Paratek Pharmaceuticals Inc. Previously, Leone served as Vice President and global corporate controller of NetApp, Inc. Earlier in her career, Leone was Vice President of Finance at Exelixis, Inc. and Vice President of Global Business Planning and Analysis at Novartis AG after the acquisition of Chiron. Leone began her career at KPMG working in the firm’s audit practice. She earned a bachelor of science in business administration and accounting from Chapman University and an executive master of business administration from St. Mary’s College. She is also a Certified Public Accountant (inactive status). She currently serves on the board of directors for Nkarta, Inc.
Liam Ratcliffe, M.D., Ph.D.
Liam Ratcliffe, M.D., Ph.D.
Liam is the head of Access Biotechnology, the strategic investment arm specializing in therapeutic platforms and products at Access Industries. Prior to his work at Access Industries, he was Managing Director at New Leaf Venture Partners, where he concentrated on biopharmaceutical investing. Prior to joining New Leaf in 2008, Liam served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Midwest region (based in Ann Arbor, Mich.) and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. He received his medical degree and doctorate in immunology from the University of Cape Town and his master of business administration from the University of Michigan. He completed his internal medicine training and fellowship in immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.
Adam Rosenberg
Adam Rosenberg
Adam is a Venture Partner at RA Capital Management. Adam currently serves on other private company boards and is Chair of Ambagon Therapeutics. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.
Simon Tate
Simon Tate
Simon is a Managing Director at Intermediate Capital Group (ICG) and has 30 years of experience in R&D. He has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, he led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen, where he assumed the role of Vice President and Head of the Pain Therapeutic Area. Prior to Convergence, Simon was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development in GSK, where he held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career. Originally trained as a Biochemist, Simon graduated from the University of Dundee, where he had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor.

News

Eliem Therapeutics Announces $60 Million Series B Financing

SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, announced the closing of a $60 million Series B financing. The financing round was led by Intermediate Capital Group (ICG) and RA Capital Management and included participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc.

Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders

SEATTLE and CAMBRIDGE, UK, 25 March 2021 – Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019. With funding from RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG), Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day.

05/24/2021
Eliem Therapeutics Announces $60 Million Series B Financing

Advances two clinical programs through topline data across four indications

Progresses two preclinical programs to potential lead candidate selection

Brings total funding since inception to $140 million

SEATTLE and CAMBRIDGE, UK –(BUSINESS WIRE) – May 24, 2021 – Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems, announced the closing of a $60 million Series B financing. The financing round was led by Intermediate Capital Group (ICG) and RA Capital Management and included participation from Access Biotechnology, Samlyn Capital, Acorn Bioventures and LifeArc. Eliem plans to use the proceeds to advance its two lead clinical-stage product candidates, ETX-810 and ETX-155, through topline data across four different indications in patients with chronic pain, depressive disorders, and epilepsy, as well as to advance its two preclinical-stage programs to selection of clinical development candidates.

“We are excited to have the continued support of our investment group, and we welcome our new investors to this latest financing round,” said Bob Azelby, President and Chief Executive Officer of Eliem Therapeutics. “This financing builds upon $80 million of prior funding, allowing for the advancement of our mission to develop life-changing therapies for debilitating neuronal excitability disorders. These disorders impact tens of millions of people worldwide and represent large commercial market opportunities. With this capital, we will continue to execute our strategy to develop differentiated small molecule new chemical entities, based on clinically validated mechanisms of action with well-established clinical and regulatory endpoints.”  

Simon Tate, Managing Director of ICG, said, “We are delighted to lead this funding round; Eliem Therapeutics is a truly exciting company and our investment reflects the overwhelming confidence we have in the team and its differentiated pipeline of clinical assets.”

Eliem is currently evaluating ETX-810, an investigational novel prodrug of the bioactive lipid palmitoylethanolamide, in two Phase 2a clinical trials in patients with diabetic peripheral neuropathic pain and lumbosacral radicular pain, with topline data expected in the first half of 2022. For its second lead product candidate, ETX-155, an investigational novel GABAA receptor positive allosteric modulator, Eliem plans to initiate two Phase 2a clinical trials, in patients with major depressive disorder and hormone-related depressive disorders, which are expected to report topline data in the second half of 2022 and the first half of 2023, respectively. In addition, for ETX-155, Eliem intends to initiate a Phase 1b clinical trial in patients with photosensitive epilepsy, that is expected to report topline data by the first half of 2022. Eliem is also progressing two preclinical programs currently in the advanced discovery stage: a novel Kv7.2/3 potassium channel opener for the potential treatment of pain and epilepsy, and a novel 2,3-benzodiazepine anxiolytic for the potential treatment of generalized anxiety disorder and depression.

About Eliem Therapeutics, Inc. 

Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. Eliem is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. Through its Series B financing, Eliem has raised an aggregate of $140 million from financings, including those of predecessor companies.

https://eliemtx.com

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.

https://racap.com/

About Access Biotechnology

Access Biotechnology is the life science investment arm of Access Industries, a privately-held industrial group with long-term holdings throughout the world. The firm leverages medical and scientific expertise to rigorously evaluate each new opportunity and collaborate with company stakeholders to meaningfully impact human health. Its investment strategy is broad, long term, and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation, and company expansion.

http://accessbio-tech.com

About Intermediate Capital Group

ICG provides capital to help companies grow. We are a global alternative asset manager with over 30 years’ history, managing €47.2bn of assets in private debt, credit and equity, principally in closed-end funds.*

We develop long-term relationships with our business partners to deliver value for shareholders, clients and employees, and use our position of influence to benefit the environment and society. We operate across four strategic asset classes: corporate, capital market, real asset and secondary investments. In addition to growing existing strategies, we innovate and pioneer new strategies where the market opportunity exists. ICG is listed on the London Stock Exchange (ticker symbol: ICP). Further details are available at www.icgam.com. You can follow ICG on LinkedIn.

*as at 31 December 2020

https://www.icgam.com/

Acorn Bioventures 

Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focused on bringing novel innovative medicines to patients. Their investment flexibility allows them to provide value across the entire spectrum from seed financings, cross-over financings, IPOs, registered direct offerings, PIPEs, open market purchases, etc. Acorn Bioventures’ investment process is based on fundamental research. They look for paradigm changing medical therapies, undiscovered or underappreciated assets, backed by outstanding teams.

www.acornbioventures.com

About LifeArc

LifeArc is a self-funded medical research charity. Our mission is to advance translation of early science into health care treatments or diagnostics that can be taken through to full development and made available to patients. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. Our success allows us to explore new approaches to stimulate and fund translation. We have our own drug discovery and diagnostics development facilities, supported by experts in technology transfer and intellectual property who also provide services to other organisations. LifeArc has a number of different funding mechanisms to invest in promising innovation for the benefit of patients. Our Philanthropic Fund provides grants to support medical research projects focused on the translation of rare diseases research. Our Early Ventures investment strategy builds on our Seed Fund portfolio of start-up companies; investing in innovative new modalities, technologies and translational research that have the potential to generate impact for patients and income that will enable us to drive further innovation.

Investors

Chris Brinzey 

Westwicke, an ICR Company

chris.brinzey@westwicke.com

339-970-2843

Media

Marites Coulter

Verge Scientific

mcoulter@vergescientific.com

415.819.2214

03/25/2021
Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders

Company advancing potentially “best-in-class” drug candidates with clinically validated mechanisms of action

Clinical programs addressing large markets with substantial unmet needs: chronic pain, depression, epilepsy, and anxiety

Leadership team brings decades of neuroscience R&D and commercialization experience

SEATTLE and CAMBRIDGE, UK, 25 March 2021 – Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched today with $80 million in financing since its inception in 2019. With funding from RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG), Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day.

The company is progressing two clinical stage assets with clinically validated mechanisms of action for neurological diseases. ETX-810, an investigational new chemical entity (NCE) for chronic pain, which acts via the palmitoylethanolamide (PEA) pathway, is being evaluated in two Phase 2a trials in lumbosacral radicular pain (chronic sciatica) and diabetic peripheral neuropathic pain. ETX-155, an investigational next generation neuroactive steroid NCE that acts as a GABAA positive allosteric modulator (PAM), is being evaluated in Phase 1 studies with plans for 2021 trial initiations in multiple indications, including major depressive disorder (MDD), hormone-related mood disorders, and focal onset seizures (FOS).

“Most patients with chronic pain and other neuronal excitability disorders struggle immensely to manage their condition with currently available treatments,” said Eliem’s President and Chief Executive Officer, Bob Azelby. “For many of these patients, the inability to execute day-to-day activities is devastating, and living a normal life can seem out of reach. We are confident that our highly experienced and dedicated team is developing treatments that can achieve meaningfully better clinical outcomes for patients, offering them the opportunity to lead the lives they were meant to live.”

Azelby most recently served as President and Chief Executive Officer of Alder BioPharmaceuticals, and before that, as Executive Vice President and Chief Commercial Officer at Juno Therapeutics. At Eliem, he is joined by a highly skilled management team – based in Seattle and Cambridge, UK – that collectively has decades of foundational experience at companies such as Amgen, GlaxoSmithKline, and Lilly as well as small biotech companies such as Alder, Juno, Exelixis, and Convergence.

“The Eliem management team knows how to develop safe and well tolerated drugs that work; and understands how to efficiently bring those treatments to patients in need,” said Andrew Levin, M.D., Ph.D., Managing Director at RA Capital Management, and Eliem co-founder and Chairman of the Board of Directors. “With an exceptionally strong and experienced leadership team, and promising preclinical and clinical data, the company has a real opportunity to transform clinically validated mechanisms of action into ‘best-in-class’ medicines.”

Eliem’s Pipeline

Eliem is currently evaluating two of its programs in clinical trials:

  • – ETX-810 is an investigational novel first-in-class, oral, non-opioid NCE being developed for chronic pain conditions.
    • Despite a massive global chronic pain market that is expected to pass $29 billion in the next decade, less than half of patients achieve a 50 percent reduction in their pain with currently approved therapies. In addition to limited efficacy, the current standard of care is hindered by dose-limiting side effects, including dizziness, sedation, gastrointestinal disturbances, as well as concerns over abuse liability.  
    • ETX-810 exerts its therapeutic effects through the PEA pathway, which is known to broadly modulate neuroinflammation and pain signaling. PEA is an endogenous bioactive lipid that has been validated as a therapeutic agent in more than 25 clinical trials across a range of chronic pain indications, where it has consistently demonstrated statistically significant reductions in pain with favorable safety and tolerability. Leveraging this data, ETX-810 was designed to significantly improve the oral bioavailability and systemic exposure of PEA to maximize the therapeutic effect. In addition to its potential to significantly reduce chronic pain, ETX-810 has no known drug-to-drug interactions or abuse liability, and in clinical testing demonstrates an encouraging safety and tolerability profile.
  • – ETX-155 is an investigational oral, next generation neuroactive steroid NCE that acts as a GABAA PAM and is being evaluated for use in depression and epilepsy.
    • MDD affects approximately 35 million adults globally, causing significant impairment to daily life. While there are effective therapies available for individuals suffering from MDD, there is considerable variability in patient responsiveness. There is a pressing need for safe, well tolerated, and rapidly acting antidepressants that reliably provide clinical improvement faster than the up to 6 weeks associated with standard of care SSRIs/SNRIs.
    • ETX-155 demonstrates dual synaptic and extrasynaptic receptor activity with an approximate 24-hour half-life and no clinically meaningful food effect. Preclinical and Phase 1 clinical data demonstrate the potential for ETX-155 to be a “best-in-class” treatment for multiple neuronal excitability disorders.

Eliem is progressing a pipeline of novel preclinical candidates with two programs currently in advanced discovery stage. As with the lead clinical programs, the preclinical programs leverage novel chemical insights and clinically validated mechanisms of action.

Eliem’s lead preclinical program is a Kv7.2/3 channel opener. This mechanism has been validated through regulatory approvals of multiple first generation Kv7.2/3 channel openers for the treatment of epilepsy and pain. These molecules showed powerful clinical efficacy but subsequently had to be withdrawn from the market due to significant safety issues. Eliem is designing its NCE to harness the efficacy of the Kv7.2/3 channel mechanism while significantly improving the safety and tolerability profile. The company expects to nominate a clinical candidate in the second half of 2021.

Leadership Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience; and is advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

Company Founders

  • Andrew Levin, M.D., Ph.D. – Managing Director, RA Capital Management, L.P.
  • Valerie Morisset, Ph.D. – Executive Vice President, R&D and Chief Scientific Officer

Company Leaders

  • Bob Azelby – President and Chief Executive Officer
  • Valerie Morisset, Ph.D. – Executive Vice President, R&D and Chief Scientific Officer
  • Erin Lavelle – Executive Vice President, Chief Operating Officer and Chief Financial Officer
  • James Bucher, J.D. – Executive Vice President and General Counsel
  • Amy Chappell, M.D. – Chief Medical Officer
  • Jo Palmer-Phillips, Ph.D. – Chief Development Officer

Board of Directors

  • Andrew Levin, M.D., Ph.D. (Chairman) – Managing Director, RA Capital Management, L.P.
  • Bob Azelby – President and Chief Executive Officer
  • Judith Dunn, Ph.D. – President of Research and Development, Fulcrum Therapeutics
  • Leone Patterson – President and Chief Financial Officer, Adverum Biotechnologies
  • Liam Ratcliffe, M.D., Ph.D. – Head of Access Biotechnology
  • Adam Rosenberg – Venture Partner, RA Capital Management, L.P.
  • Simon Tate – Managing Director, Intermediate Capital Group (ICG)

About Eliem Therapeutics, Inc

Eliem Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for neuronal excitability disorders with the goal of restoring balance in both the peripheral and central nervous systems to help patients live on their own terms. Eliem channels its experience, energy, and passion for improving patients’ quality of life by developing life-changing novel therapies for disorders such as chronic pain, depression, epilepsy, focal onset seizures, and anxiety – conditions that make simple daily activities challenging for impacted patients. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

https://eliemtx.com/

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, allowing management teams to drive value creation from inception through commercialization.

https://racap.com/

About Access Biotechnology

Access Biotechnology is the life science investment arm of Access Industries, a privately-held industrial group with long-term holdings throughout the world. The firm leverages medical and scientific expertise to rigorously evaluate each new opportunity and collaborate with company stakeholders to meaningfully impact human health. Its investment strategy is broad, long term, and aims to enable truly innovative therapeutic platforms and products across three key stages: company foundation, technology translation, and company expansion.

http://accessbio-tech.com

About Intermediate Capital Group

ICG provides capital to help companies grow. We are a global alternative asset manager with over 30 years’ history, managing €47.2bn of assets in private debt, credit and equity, principally in closed-end funds.*

We develop long-term relationships with our business partners to deliver value for shareholders, clients and employees, and use our position of influence to benefit the environment and society. We operate across four strategic asset classes: corporate, capital market, real asset and secondary investments. In addition to growing existing strategies, we innovate and pioneer new strategies where the market opportunity exists. ICG is listed on the London Stock Exchange (ticker symbol: ICP). Further details are available at www.icgam.com. You can follow ICG on LinkedIn.

*as at 31 December 2020

https://www.icgam.com/

Contacts

Media

Sarah Sutton
Finsbury Glover Hering (FGH)
sarah.sutton@fgh.com
518-932-3680

Ben Waldron
Finsbury Glover Hering (FGH)
ben.waldron@fgh.com
347-622-3740

Careers

We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.

We’d love to connect.

Open Positions
Global Study Lead
Global Study Lead

Location: Cambridge UK or Greater Seattle Area, Washington

About Eliem:Eliem Therapeutics is a small, ambitious and fast-growing biotech company developing medicines for patients with neurologic diseases. Our pipeline includes two clinical stage assets. We are looking to welcome two experienced clinical study mangers with early/mid phase drug development experience. This is a great time to become part of the team and experience first-hand working in the Biotech industry. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com


About this role:

You will be responsible for providing oversight and management of Eliem sponsored Phase 1-3 studies to ensure that they are conducted to appropriate corporate and regulatory standards.


Key Responsibilities:

  • Set-up and management of Eliem Phase 1-3 sponsored studies, ensuring they are conducted to appropriate corporate and regulatory standards, including oversight of clinical conduct, drug supply, regulatory submissions, data management and statistical activities to clinical study report finalization.
  • Responsible for management of clinical study budgets and timelines, and for ensuring that forecasted budgets and schedules are met.
  • Responsible for oversight and management of Clinical Service Providers, CROs and external consultants.
  • Responsible for authoring, contributing and review of study documents including protocols, amendments, regulatory documents, informed consent, monitoring reports and study plans.
  • Works with the wider clinical team, including scientists and medics, to develop the study design and may input into overall clinical development plan.
  • Responsible for ensuring that the eTMF is maintained in accordance with the TMF plan.
  • Participation at investigator meetings and co-monitoring of clinical studies.

Key Requirements:

Essential:

  • A Bachelor’s Degree or equivalent in a relevant field preferably Biological / Life Sciences, or equivalent experience
  • Around 5-7 years demonstrable Clinical Development/Operations experience gained within the pharmaceutical industry
  • We are looking to welcome two experienced clinical study managers with early/mid phase drug development experience.
  • This is a great time to become part of the team and experience first-hand working in the Biotech industry.
  • Experience of global study oversight including some experience of US trial management
  • Experience in managing multiple projects and priorities.
  • Experience managing internal and external resources.
  • Strong working knowledge of GCP/ICH guidelines.
  • Knowledge of other related drug development functions.
  • Excellent communication and influencing skills
  • Self-motivated and able to work independently

Desirable:

  • Experience in both early and late phase clinical trials

We offer our employees competitive salary and benefits, including pension, life assurance, private medical insurance and share options.

To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E21/02. 

Clinical Trials Associate
Clinical Trials Associate

Location: Cambridge UK or Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a privately held clinical-stage company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and has funding from leading healthcare investors including RA Capital and Access Biotechnology.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com


About this role:

We have a new opportunity in our expanding Clinical team for an experienced Clinical Trials Associate to provide operational support to the clinical trial process, contributing to a wide range of tasks related to site management and/or study management and oversight activities, as delegated by the study managers.


Key Responsibilities:

  • Provide day-to-day support to study managers on global clinical trial activities, such as creating/updating study trackers and timelines, managing contract executions and filing
  • Actively contribute to the development, review and updates to clinical trial documents and study plans
  • Ensure TMF filing and maintenance is completed routinely
  • Review and track study / vendor invoices, including invoice accuracy, comparison to contract and outstanding payments
  • Confirm that all clinical trial documents have been collected to support site initiation
  • Coordinate and provide minutes for meetings/conference calls
  • Work closely with vendors to track performance, escalating any performance and quality issues
  • Interact with internal matrix partners and external partners including Investigators and site staff
  • Conduct study file audits, including report and resolution of findings
  • Conduct quality control review of documents
  • Participate in process improvement initiatives
  • May be responsible for supporting multiple studies simultaneously and must prioritize appropriately to meet business needs

Key Requirements:

  • Bachelor’s degree, or equivalent relevant experience, in Life Sciences or a related field
  • 3-5 years’ experience in the pharmaceutical industry or health related field
  • Knowledge of the clinical development process and FDA/ICH/GCP regulations
  • Excellent communication skills and attention to detail
  • Ability to work well in a team environment
  • Excellent attention to detail and quality standard
  • Proficient IT skills, including MS Office

We offer our employees competitive salary and benefits.

To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E21/03.

Clinical Trials Associate

Location: Cambridge UK or Greater Seattle Area, Washington

About Eliem:

Eliem Therapeutics is a privately held clinical-stage company developing medicines for patients with neurologic diseases.  Our pipeline has two clinical stage compounds in conditions focused on pain and other neurological conditions.  The company continues to grow its preclinical pipeline in neurology.

Eliem launched in 2018 and has funding from leading healthcare investors including RA Capital and Access Biotechnology.  The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com


About this role:

We have a new opportunity in our expanding Clinical team for an experienced Clinical Trials Associate to provide operational support to the clinical trial process, contributing to a wide range of tasks related to site management and/or study management and oversight activities, as delegated by the study managers.


Key Responsibilities:

  • Provide day-to-day support to study managers on global clinical trial activities, such as creating/updating study trackers and timelines, managing contract executions and filing
  • Actively contribute to the development, review and updates to clinical trial documents and study plans
  • Ensure TMF filing and maintenance is completed routinely
  • Review and track study / vendor invoices, including invoice accuracy, comparison to contract and outstanding payments
  • Confirm that all clinical trial documents have been collected to support site initiation
  • Coordinate and provide minutes for meetings/conference calls
  • Work closely with vendors to track performance, escalating any performance and quality issues
  • Interact with internal matrix partners and external partners including Investigators and site staff
  • Conduct study file audits, including report and resolution of findings
  • Conduct quality control review of documents
  • Participate in process improvement initiatives
  • May be responsible for supporting multiple studies simultaneously and must prioritize appropriately to meet business needs

Key Requirements:

  • Bachelor’s degree, or equivalent relevant experience, in Life Sciences or a related field
  • 3-5 years’ experience in the pharmaceutical industry or health related field
  • Knowledge of the clinical development process and FDA/ICH/GCP regulations
  • Excellent communication skills and attention to detail
  • Ability to work well in a team environment
  • Excellent attention to detail and quality standard
  • Proficient IT skills, including MS Office

We offer our employees competitive salary and benefits.

To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E21/03.

Global Study Lead

Location: Cambridge UK or Greater Seattle Area, Washington

About Eliem:Eliem Therapeutics is a small, ambitious and fast-growing biotech company developing medicines for patients with neurologic diseases. Our pipeline includes two clinical stage assets. We are looking to welcome two experienced clinical study mangers with early/mid phase drug development experience. This is a great time to become part of the team and experience first-hand working in the Biotech industry. The company has locations in the Greater Seattle Area, WA and Cambridge, UK. For further information visit our website: https://eliemtx.com


About this role:

You will be responsible for providing oversight and management of Eliem sponsored Phase 1-3 studies to ensure that they are conducted to appropriate corporate and regulatory standards.


Key Responsibilities:

  • Set-up and management of Eliem Phase 1-3 sponsored studies, ensuring they are conducted to appropriate corporate and regulatory standards, including oversight of clinical conduct, drug supply, regulatory submissions, data management and statistical activities to clinical study report finalization.
  • Responsible for management of clinical study budgets and timelines, and for ensuring that forecasted budgets and schedules are met.
  • Responsible for oversight and management of Clinical Service Providers, CROs and external consultants.
  • Responsible for authoring, contributing and review of study documents including protocols, amendments, regulatory documents, informed consent, monitoring reports and study plans.
  • Works with the wider clinical team, including scientists and medics, to develop the study design and may input into overall clinical development plan.
  • Responsible for ensuring that the eTMF is maintained in accordance with the TMF plan.
  • Participation at investigator meetings and co-monitoring of clinical studies.

Key Requirements:

Essential:

  • A Bachelor’s Degree or equivalent in a relevant field preferably Biological / Life Sciences, or equivalent experience
  • Around 5-7 years demonstrable Clinical Development/Operations experience gained within the pharmaceutical industry
  • We are looking to welcome two experienced clinical study managers with early/mid phase drug development experience.
  • This is a great time to become part of the team and experience first-hand working in the Biotech industry.
  • Experience of global study oversight including some experience of US trial management
  • Experience in managing multiple projects and priorities.
  • Experience managing internal and external resources.
  • Strong working knowledge of GCP/ICH guidelines.
  • Knowledge of other related drug development functions.
  • Excellent communication and influencing skills
  • Self-motivated and able to work independently

Desirable:

  • Experience in both early and late phase clinical trials

We offer our employees competitive salary and benefits, including pension, life assurance, private medical insurance and share options.

To apply please send your CV and a covering letter to CareersUK@eliemtx.com, quoting job reference E21/02. 

Contact Us

MEDIA
INVESTOR RELATIONS
HUMAN RESOURCES
PARTNERING
Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053

Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT